Ani Pharmaceuticals (ANIP) Inventory Average (2013 - 2026)

Ani Pharmaceuticals has disclosed Inventory Average across 14 years of filings, most recently posting $143.3 million for Q1 2026.

• Inventory Average for Q1 2026 came in at $143.3 million, up 4.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $143.3 million (up 4.5% YoY), and the FY2025 annual result was $139.9 million, up 12.85% from the prior year.
• Inventory Average came in at $143.3 million for Q1 2026 at Ani Pharmaceuticals, down from $144.8 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $144.8 million in Q4 2025 to a low of $82.4 million in Q1 2022.
• The 5-year median for Inventory Average is $112.5 million (2024), against an average of $118.9 million.
• Across the five-year window, Inventory Average surged 52.61% in 2022 and advanced 1.66% in 2025, its largest moves.
• Ani Pharmaceuticals' Inventory Average stood at $105.3 million in 2022, then increased by 3.37% to $108.9 million in 2023, then soared by 30.78% to $142.4 million in 2024, then advanced by 1.66% to $144.8 million in 2025, then retreated by 1.04% to $143.3 million in 2026.
• The last three Inventory Average figures came in at $143.3 million (Q1 2026), $144.8 million (Q4 2025), and $142.4 million (Q3 2025), per Business Quant data.